First Wave BioPharma Inc FWBI:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/27/23 EST
5.43UNCH (UNCH)
Volume
2,472
Close
5.43quote price arrow down-0.25 (-4.40%)
Volume
395,390
52 week range
3.01 - 348.60
Loading...
  • Open5.60
  • Day High5.82
  • Day Low5.20
  • Prev Close5.68
  • 52 Week High348.60
  • 52 Week High Date02/10/22
  • 52 Week Low3.01
  • 52 Week Low Date12/23/22

Key Stats

  • Market Cap5.403M
  • Shares Out995,000.00
  • 10 Day Average Volume2.27M
  • Dividend-
  • Dividend Yield-
  • Beta1.64
  • YTD % Change-11.41

KEY STATS

  • Open5.60
  • Day High5.82
  • Day Low5.20
  • Prev Close5.68
  • 52 Week High348.60
  • 52 Week High Date02/10/22
  • 52 Week Low3.01
  • 52 Week Low Date12/23/22
  • Market Cap5.403M
  • Shares Out995,000.00
  • 10 Day Average Volume2.27M
  • Dividend-
  • Dividend Yield-
  • Beta1.64
  • YTD % Change-11.41

RATIOS/PROFITABILITY

  • EPS (TTM)-319.47
  • P/E (TTM)-0.02
  • Fwd P/E (NTM)-0.75
  • EBITDA (TTM)-19.053M
  • ROE (TTM)-2,512.64%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date03/31/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On First Wave BioPharma Inc

 

Profile

MORE
First Wave BioPharma, Inc. is engaged in the research and development of targeted, non-systemic therapies for the treatment for gastrointestinal (GI) diseases. The Company is focused on developing its pipeline of gut-restricted GI clinical product candidates, including niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, which is a recombinant lipase enzyme designed to enable the digestion of fats and...
James Sapirstein
Chairman of the Board, President, Chief Executive Officer
Sarah Romano
Chief Financial Officer
Address
777 Yamato Road, Suite 502
Boca Raton, FL
33431
United States